Anticoagulant activities of high and low molecular weight heparin fractions. 1979

T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas

The anticoagulant activities of high and low molecular weight heparin fractions were measured by three assay methods, both in vitro, and after intravenous injection in volunteers. The low molecular weight (LMW) fraction had similar anti-Xa activity in vitro to the high molecular weight (HMW) fraction, but in APTT assays the HMW fraction was about twice as potent. After intravenous injection, the two fractions gave equal heparin levels by anti-Xa assays, but in APTT assays using synthetic substrate S-2222 gave about 20% lower levels than anti-Xa clotting assays for both heparins. Complete protamine neutralization of the post-injection heparin activity was found in APTT and synthetic substrate assays, but about 20% of the clotting anti-Xa effect could not be neutralized. Complete neutralization of the fractions by protamine was shown by all three assays in vitro. This non-neutralizable activity probably accounts for the difference between the anti-Xa clotting and synthetic substrate assays. Studies by crossed immunoelectrophoresis and affinity chromatography indicated that the antithrombin III binding properties of the two fractions were similar.

UI MeSH Term Description Entries
D007123 Immunoelectrophoresis, Two-Dimensional Immunoelectrophoresis in which a second electrophoretic transport is performed on the initially separated antigen fragments into an antibody-containing medium in a direction perpendicular to the first electrophoresis. Immunoelectrophoresis, Crossed,Immunoelectrophoresis, 2-D,Immunoelectrophoresis, 2D,2-D Immunoelectrophoresis,2D Immunoelectrophoresis,Crossed Immunoelectrophoresis,Immunoelectrophoresis, 2 D,Immunoelectrophoresis, Two Dimensional,Two-Dimensional Immunoelectrophoresis
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011479 Protamines A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692) Protamine,Protamine Sulfate,Protamine Chloride,Chloride, Protamine,Sulfate, Protamine
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
December 1986, Thrombosis research,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
August 1985, European journal of clinical investigation,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
November 1991, Thrombosis research,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
February 1992, Thrombosis research,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
January 1987, Nouvelle revue francaise d'hematologie,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
December 2010, Journal of controlled release : official journal of the Controlled Release Society,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
October 1988, Biulleten' eksperimental'noi biologii i meditsiny,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
March 1992, Thrombosis research,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
January 1980, Thrombosis research,
T W Barrowcliffe, and E A Johnson, and C A Eggleton, and G Kemball-Cook, and D P Thomas
January 1984, Therapie,
Copied contents to your clipboard!